COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) b.i.d. was slightly less than that seen with the concomitant administration of 0.5% timolol b.i.d. and 2.0% dorzolamide t.i.d. (see CLINICAL PHARMACOLOGY, Clinical Studies).

The dose is one drop of COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) in the affected eye(s) two times daily.

If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart (see also PRECAUTIONS: DRUG INTERACTIONS).

COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) Ophthalmic Solution is a clear, colorless to nearly colorless, slightly viscous solution.

No. 3628 — COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) Ophthalmic Solution is supplied in an OCUMETER®* PLUS container, a white, translucent, HDPE plastic ophthalmic dispenser with a controlled drop tip and a white polystyrene cap with dark blue label as follows:

NDC 0006-3628-36, 10 mL in an 18 mL capacity bottle.

Storage

Store COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) at 15-30°C (59-86°F). Protect from light.

Manuf. for: Merck & Co Inc,Whitehouse Station, NJ 08889, USA. Manuf By: Laboratories Merck Sharp & Dohme-Chibret 63963 Clermont-Ferrand Cedex 9, France. Issued October 2009.

Last reviewed on RxList: 7/20/2010
This monograph has been modified to include the generic and brand name in many instances.